medigraphic.com
ISSN 1561-302X (Print)

2019, Number 3

Next >>

Rev cubana med 2019; 58 (3)

Hepatic steatosis in type 2 diabetes patients and its relationship with glycemic control

Buchaca FEF, Bonilla RJL, Rodríguez AMA, Hernández CJL, Rodríguez AL, Rodríguez HR

Language: Spanish
References: 19
Page: 1-11
PDF size: 305.73 Kb.


ABSTRACT

Introduction: Non-alcoholic liver steatosis is the most frequent disease in the world. It is associated with type 2 diabetes mellitus, representing great economic-social impact.
Objective: To describe the behavior of hepatic steatosis in a population of patients diagnosed with type 2 diabetes mellitus.
Methods: An observational, descriptive, cross-sectional study was conducted in 94 diabetic patients treated at Hermanos Ameijeiras Clinical Surgical Hospital, from February 2016 to February 2018.
Results: Steatosis was mild in 42.6%, moderate (44.7%) and severe in 12.8%, with a mainly indeterminate NAFLD score (72.3%). F0-1 fibrosis was detected in 58.5% of the patients, F2 (29.8%) and significant (F3 and F4) in 11.7%). Association between increased liver echogenicity, diffuse liver pattern and severe degree of steatosis were ostensible by ultrasound with higher degree of fibrosis according to elastography. Significant relationship of elevated levels of HBA1C with significant fibrosis was detected, measured both by NAFLD score and by elastography.
Conclusions: Hepatic steatosis present in patients with diabetes mellitus was mainly mild to moderate with prevalence of mild fibrosis, the degree of significant fibrosis was associated with increased liver echogenicity, diffuse liver pattern, severe degree of steatosis by ultrasound and high levels of hemoglobin. glycosylated.


REFERENCES

  1. Machado MV. Review of non-alcoholic fatty liver disease. World J Gastroenterol. 2014;20(36):12956-80.

  2. Lomonaco R, Chen J, Cusi K. An endocrine perspective of non alcoholic fatty liver disease (NAFLD). Ther Adv Endocrinol Metab. 2011;2(5):211-25.

  3. Alkhouri N, McCullough AJ. Non invasive diagnosis of NASH and liver fibrosis within the spectrum of NAFLD. Gastroenterol Hepatol. 2012;8(10):661-8.

  4. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander- Tetri BA, Bacon BR. Non alcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999;94:2467-74.

  5. Laclé Murray A, Esquivel Chaverri M, Madrigal López M, Alpízar Chacón C. Prevalencia de esteatosis hepática no alcohólica en personas diabéticas tipo 2. Acta Med Costarric. 2014;56(1):17-22.

  6. Real JT, Folgado J, Molina Méndez M, Martínez Hervás S, Peiro M, Ascaso JF. Homocisteína plasmática, Lp(a) y marcadores de estrés oxidativo en la vasculopatía periférica del paciente con diabetes tipo 2. Clin Investig Arterioscler. 2016;28:178-87.

  7. Yanes Quesada M, Cruz Hernández J, Yanes Quesada MA, Calderín Bouza R, Pardías Milán L, Vázquez Díaz G. Diabetes mellitus en el anciano, un problema frecuente. Rev Cubana Med Gen Integr. 2009[acceso: 02/01/2019];25(2). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-21252009000200011&lng=es

  8. Escobedo J, Buitrón L, Velasco M, Ramirez J, Hernández R, MacChia A, et al. High prevalence of diabetes and impaired fasting glucose in urban Latin America: The CARMELA Study. Diabet Med. 2009;26:864-71.

  9. Padrón González O, Crespo Fernández DA, Breijo H, Gil Figueroa BV, Sandrino Sánchez M. Características epidemiológicas y clínicas de los ancianos con diabetes mellitus. Rev. Ciencias Médicas. 2013;17(4):2-10.

  10. Gonzáles Grández NN, Rodríguez Lay EG, Manrique Hurtado H. Características clínicas y factores asociados a morbilidad intrahospitalaria en los pacientes con diabetes mellitus tipo 2. Rev Soc Perú Med Interna. 2013;26(4):159-65.

  11. Ochoa E, Calambás F. Hígado graso no alcohólico en consulta de gastroenterología. Repert Med Cir. 2017;26(4):225-30.

  12. Araya Q, Valera J, Contreras J. Alteraciones de la tolerancia a la glucosa y frecuencia de síndrome metabólico en pacientes con enfermedad por hígado graso no alcohólico. Rev Med Chile. 2006;134(9):1092-8.

  13. Balarezo García MG, Montoya López AA. Principales factores de riesgo para diabetes mellitus tipo 2 en adultos mayores ingresados en el servicio de medicina interna del Hospital Provincial General Docente Riobamba en el periodo enero 2009-diciembre 2011. Tesis de grado para la obtención del título de: Médico General. Universidad de Riobamba. Riobamba; Ecuador. 2013.

  14. Razvodovsky YE. Aggregate level association between alcohol and diabetes mellitus mortality rate. Ann Intern Med. 2016;18(3):275-82.

  15. Fracanzani AL, Valenti L, Bugianesi E, Vanni E, Grieco A, Miele L, et al. Risk of non alcoholic steatohepatitis and fibrosis in patients with non alcoholic fatty liver disease and low visceral adiposity. J Hepatol. 2011;54(6):1244-9.

  16. Sanjinez Asbún M, Nishi C, López Bilbao La Vieja I, Urquizo Ayala G. Prevalencia de esteatosis hepática no alcohólica en pacientes diabéticos tipo 2, con o sin síndrome metabólico. Rev Med La Paz. 2017;23(1):12-8.

  17. Llopis Sanchis M, Rosseti P, Cioaia S, Martínez Pascual M, Poquet Català I, Bourguet M, et al. Evaluación del grado de fibrosis hepática en pacientes con diabetes mellitus tipo 1 mediante la utilización del fibroscan. Rev Clin Esp. 2017;217(8):479-85.

  18. Amarapurkar DN. Non alcoholic steatohepatitis (NASH) with diabetes. predictors of liver fibrosis. Annals of Hepatology. 2006;5(1):30-3.

  19. Roldán Valdés E, Favila R, Martínez López M, Uribe M, Méndez Sánchez N. Imaging techniques for assessing hepatic fat content in non alcoholic fatty liver disease. Ann Hepatol. 2008;7:204-12.




2020     |     www.medigraphic.com